Gut Microbiota Modulation Attenuates Myocardial Ischemia-Reperfusion Injury in Diabetic Mice
Fecal microbiota transplantation from lean donors reduced myocardial infarct size in diabetic mice subjected to ischemia-reperfusion injury.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
FMT significantly reduced infarct size as a percentage of area at risk (38.7% vs 58.7%, p=0.003) in db/db T2DM mice. Microbiome analysis showed modest but significant beta-diversity shift and identified Akkermansia muciniphila as a candidate taxon depleted in diabetic mice and partially restored after FMT. Alpha-diversity differences were limited to the Simpson index.
How it was done
Male db/db mice received a 14-day FMT course from lean db/m donors or vehicle following antibiotic pretreatment; myocardial IRI was surgically induced and infarct size quantified; gut microbiota assessed by 16S rRNA gene sequencing.
Risk of bias
Study conducted exclusively in a murine animal model with no human validation. The protective mechanism is not characterized in the abstract, and full-text inaccessibility limits comprehensive methodological appraisal.
What this study does NOT prove
A causal role for A. muciniphila in cardioprotection cannot be established, nor can protection be extrapolated to human ischemia-reperfusion settings.
In clinical practice
Findings are not transferable to clinical practice. FMT as cardioprotection in diabetic patients remains purely experimental.
Limitations
Study conducted exclusively in a murine animal model with no human validation. The protective mechanism is not characterized in the abstract, and full-text inaccessibility limits comprehensive methodological appraisal.
Technical appendix
Version history
- 1.0 · 2026-07-25 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.